NCT04398745 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 10
- group Id
- BG001
- value
- 9
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 5
- group Id
- BG004
- value
- 8
- group Id
- BG005
- value
- 36
- units
- Participants
- groups
- description
- Participants with Relapsed/Refractory Multiple Myeloma (RRMM) who have had at least 3 lines of prior treatment (or at least 2 lines of prior treatment if ineligible for autologous stem cell transplantation) and normal/mildly impaired renal function received intravenous (IV) infusion of 2.5 milligram (mg)/kilogram (kg) belantamab mafodotin for 30 minutes on Day 1 of every 21-day Cycle until disease progression, withdrawal of consent, withdrawal due to adverse event (AE), lost to follow-up, death, whichever occurs first.
- id
- BG000
- title
- Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)
- description
- Participants with RRMM who have had at least 3 lines of prior treatment (or at least 2 lines of prior treatment if ineligible for autologous stem cell transplantation) and severe renal impairment renal function received IV infusion of 2.5 mg/kg belantamab mafodotin for 30 minutes on Day 1 of every 21-day Cycle until disease progression, withdrawal of consent, withdrawal due to AE, lost to follow-up, death, whichever occurs first.
- id
- BG001
- title
- Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
- description
- Participants with RRMM who have had at least 3 lines of prior treatment (or at least 2 lines of prior treatment if ineligible for autologous stem cell transplantation) and other renal impairment renal function received IV infusion of 2.5 mg/kg belantamab mafodotin for 30 minutes on Day 1 of every 21-day Cycle until disease progression, withdrawal of consent, withdrawal due to AE, lost to follow-up, death, whichever occurs first.
- id
- BG002
- title
- Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)
- description
- Participants with RRMM who have had at least 3 lines of prior treatment (or at least 2 lines of prior treatment if ineligible for autologous stem cell transplantation) and end stage renal disease (ESRD) (not on hemodialysis) received IV infusion of 2.5 mg/kg belantamab mafodotin for 30 minutes on Day 1 of every 21-day Cycle until disease progression, withdrawal of consent, withdrawal due to AE, lost to follow-up, death, whichever occurs first.
- id
- BG003
- title
- Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)
- description
- Participants with RRMM who have had at least 3 lines of prior treatment (or at least 2 lines of prior treatment if ineligible for autologous stem cell transplantation) and ESRD (on hemodialysis) received IV infusion of 2.5 mg/kg belantamab mafodotin for 30 minutes on Day 1 of every 21-day Cycle until disease progression, withdrawal of consent, withdrawal due to AE, lost to follow-up, death, whichever occurs first.
- id
- BG004
- title
- Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
- description
- Total of all reporting groups
- id
- BG005
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 8.21
- value
- 60.3
- group Id
- BG001
- spread
- 6.11
- value
- 74.6
- group Id
- BG002
- spread
- 10.79
- value
- 67.5
- group Id
- BG003
- spread
- 5.22
- value
- 81.4
- group Id
- BG004
- spread
- 6.83
- value
- 70.9
- group Id
- BG005
- spread
- 10.00
- value
- 69.9
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- YEARS
- classes
- categories
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 11
- title
- Female
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 8
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 4
- group Id
- BG004
- value
- 6
- group Id
- BG005
- value
- 25
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 11
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 4
- group Id
- BG005
- value
- 7
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 18
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 10
- group Id
- BG001
- value
- 9
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 5
- group Id
- BG004
- value
- 8
- group Id
- BG005
- value
- 36
- units
- Participants
- groups
- description
- Participants with Relapsed/Refractory Multiple Myeloma (RRMM) who have had at least 3 lines of prior treatment (or at least 2 lines of prior treatment if ineligible for autologous stem cell transplantation) and normal/mildly impaired renal function received intravenous (IV) infusion of 2.5 milligram (mg)/kilogram (kg) belantamab mafodotin for 30 minutes on Day 1 of every 21-day Cycle until disease progression, withdrawal of consent, withdrawal due to adverse event (AE), lost to follow-up, death, whichever occurs first.
- id
- BG000
- title
- Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)
- description
- Participants with RRMM who have had at least 3 lines of prior treatment (or at least 2 lines of prior treatment if ineligible for autologous stem cell transplantation) and severe renal impairment renal function received IV infusion of 2.5 mg/kg belantamab mafodotin for 30 minutes on Day 1 of every 21-day Cycle until disease progression, withdrawal of consent, withdrawal due to AE, lost to follow-up, death, whichever occurs first.
- id
- BG001
- title
- Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
- description
- Participants with RRMM who have had at least 3 lines of prior treatment (or at least 2 lines of prior treatment if ineligible for autologous stem cell transplantation) and other renal impairment renal function received IV infusion of 2.5 mg/kg belantamab mafodotin for 30 minutes on Day 1 of every 21-day Cycle until disease progression, withdrawal of consent, withdrawal due to AE, lost to follow-up, death, whichever occurs first.
- id
- BG002
- title
- Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)
- description
- Participants with RRMM who have had at least 3 lines of prior treatment (or at least 2 lines of prior treatment if ineligible for autologous stem cell transplantation) and end stage renal disease (ESRD) (not on hemodialysis) received IV infusion of 2.5 mg/kg belantamab mafodotin for 30 minutes on Day 1 of every 21-day Cycle until disease progression, withdrawal of consent, withdrawal due to AE, lost to follow-up, death, whichever occurs first.
- id
- BG003
- title
- Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)
- description
- Participants with RRMM who have had at least 3 lines of prior treatment (or at least 2 lines of prior treatment if ineligible for autologous stem cell transplantation) and ESRD (on hemodialysis) received IV infusion of 2.5 mg/kg belantamab mafodotin for 30 minutes on Day 1 of every 21-day Cycle until disease progression, withdrawal of consent, withdrawal due to AE, lost to follow-up, death, whichever occurs first.
- id
- BG004
- title
- Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
- description
- Total of all reporting groups
- id
- BG005
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 8.21
- value
- 60.3
- group Id
- BG001
- spread
- 6.11
- value
- 74.6
- group Id
- BG002
- spread
- 10.79
- value
- 67.5
- group Id
- BG003
- spread
- 5.22
- value
- 81.4
- group Id
- BG004
- spread
- 6.83
- value
- 70.9
- group Id
- BG005
- spread
- 10.00
- value
- 69.9
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- YEARS
- classes
- categories
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 11
- title
- Female
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 8
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 4
- group Id
- BG004
- value
- 6
- group Id
- BG005
- value
- 25
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 11
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 4
- group Id
- BG005
- value
- 7
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 18
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle